Galapagos NV
Saved Wikipedia (April 17, 2023) for "Galapagos NV"
https://en.wikipedia.org/wiki/Galapagos_NV
2023-04-17-wikipedia-org-galapagos-nv.pdf
https://drive.google.com/file/d/1RNYGS8ytpA_WiOV66jXL38hv8bMGYbSP/view?usp=share_link
Formerly : [Galapagos Genomics] NV
Type : Naamloze vennootschap
Traded as : Euronext Brussels: GLPG / BEL 20 component
Industry : Pharmaceutical
Founded : 1999
Key people : Onno van de Stolpe (CEO), Raj Parekh (Chairman)
Products : filgotinib; GLPG1205; GLPG0778
Revenue : €288.836 million (2018)[1]
Net income : €-29.259 million (2018)[1]
Total assets : €1,439.496 million (2018)[1]
Total equity : €1,214.249 million (2018)[1]
Number of employees : 725 (2018)[1]
Website : www.glpg.com
Galapagos NV (formerly known as [Galapagos Genomics]) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. The outgoing CEO is the Dutchman Onno van de Stolpe and his replacement is Paul Stoffels, effective April 1, 2022. [2]
The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.[3]
History
Galapagos (Leiden branch, 2022)
[Galapagos Genomics] NV was founded in 1999 as a joint venture between [Crucell] and Tibotec.[4] The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.[5]
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
In 2019, [Gilead Sciences] and Galapagos entered into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.[6]
In June 2022, the business announced it would acquire CellPoint for €125 million, with milestones of up to €100 million and AboundBio for $14million.[7]
Drugs currently under development
Filgotinib (GLPG0634) a selective inhibitor of JAK1 (Janus kinase 1) being developed for the treatment of rheumatoid arthritis and potentially Crohn's disease.
GLPG1205: a first-in-class GPR84-inhibitor currently under research for the treatment of inflammatory bowel disease.
See also
References
- a b c d e "Galapagos Annual Report 2018". Galapagos.
- ^ "Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO". Reuters. 26 January 2022.
- ^ Todd Campbel (9 June 2016). "Why Galapagos NV Shares Soared 30.5% in May". The Motley Fool.
- ^ "History". Galapagos.
- ^ "Galapagos Genomics gaat zelf medicijnen ontwikkelen" [Galapagos Genomics to develop medicines themselves]. Het Nieuwsblad (in Dutch). 16 April 2005.
- ^ Gilead and Galapagos Enter Into Transformative Research and Development Collaboration, PM Gilead July 14, 2019, Retrieved 2020-05-09
- ^ "Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies".